View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 22, 2020updated 02 Dec 2021 6:17am

Glenmark gets regulatory approval for Favipiravir to treat Covid-19

India-based Glenmark Pharmaceuticals has secured regulatory approval for the manufacturing and marketing of antiviral drug Favipiravir under the brand name FabiFlu to treat mild to moderate Covid-19.

India-based Glenmark Pharmaceuticals has secured regulatory approval for the manufacturing and marketing of antiviral drug Favipiravir under the brand name FabiFlu to treat mild to moderate Covid-19.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

The approval, granted under an accelerated process, marks the first authorisation for oral Favipiravir in India for this indication.

Since 2014, Favipiravir holds approval in Japan to treat new or re-emerging influenza virus infections. In cells, the drug is converted into an active phosphoribosylated form (favipiravir-RTP), which is identified by viral RNA polymerase as a substrate, in turn blocking RNA polymerase activity.

Glenmark developed the active pharmaceutical ingredient (API ) and the formulation for the drug in-house. The company then applied for and obtained regulatory approval to assess the drug in Phase III trials for mild to moderate Covid-19.

According to the company, Favipiravir demonstrated promising clinical evidence, with positive results in mild to moderate Covid-19 cases. Clinical improvement was observed in age groups of 20 to >90 years.

The drug is said to provide rapid decrease in viral load within four days, along with quicker symptomatic and radiological improvement. Favipiravir demonstrated up to 88% of clinical improvement in patients with mild to moderate Covid-19.

Glenmark said that mild to moderate Covid-19 patients with co-morbid conditions such as diabetes and heart disease can also use the drug.

Glenmark Pharmaceuticals chairman and managing director Glenn Saldanha said: “FabiFlu has demonstrated an encouraging response in mild to moderate Covid-19 patients during clinical trials. Moreover, it is orally administered, and so it serves as a more convenient treatment option over other intravenously administered medications.

“Glenmark will work closely with the government and medical community to make FabiFlu quickly accessible to patients across the country.”

The drug will be available for prescription use at INR103 ($1.35) per tablet.

Last month, Glenmark launched a Phase III trial to assess Favipiravir in combination with antiviral drug Umifenovir for the treatment of Covid-19 in India.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology